Adverse histopathological findings as a guide to patient management after curative resection of node-positive colonic cancer

被引:32
作者
Chapuis, PH
Dent, OF
Bokey, EL
Newland, RC
Sinclair, G
机构
[1] Univ Sydney, Concord Hosp, Dept Colorectal Surg, Sydney, NSW 2139, Australia
[2] Concord Hosp, Div Anat Pathol, Sydney, NSW, Australia
关键词
D O I
10.1002/bjs.4389
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: The aim of this study was to identify patient and turnout characteristics that might assist in developing an improved approach to patient selection for chemotherapy after resection of clinicopathological stage C colonic cancer. Methods: Clinical, pathological and follow-up data have been collected prospectively for all patients undergoing resection for colorectal cancer at Concord Hospital since 1971. From an initial 2980 patients, after exclusions 378 remained who had a potentially curative operation for colonic cancer with nodal metastases and did not receive adjuvant chemotherapy. Associations between several pathological features and survival were examined by proportional hazards regression. Results. In a multivariate model, both overall and colonic cancer-specific survival rates were negatively associated with serosal surface involvement, apical node metastasis, high histological grade and venous invasion. The survival of patients with stage C disease who had none of these adverse features was not significantly different from that of patients with stage B lesions. However, survival diminished significantly when one or more of the adverse features were present. Conclusion: Patients with a stage C turnout but with none of the identified adverse features experience relatively good survival and are unlikely to benefit from adjuvant chemotherapy. In this series such patients accounted for 40.5 per cent of patients with stage C disease.
引用
收藏
页码:349 / 354
页数:6
相关论文
共 22 条
[1]   DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study [J].
Barratt, PL ;
Seymour, MT ;
Stenning, SP ;
Georgiades, I ;
Walker, C ;
Birbeck, K ;
Quirke, P .
LANCET, 2002, 360 (9343) :1381-1391
[2]  
Bellemare S, 1998, ANN CHIR, V52, P711
[3]   Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer [J].
Bleeker, WA ;
Hayes, VM ;
Karrenbeld, A ;
Hofstra, RMW ;
Verlind, E ;
Hermans, J ;
Poppema, S ;
Buys, CHCM ;
Plukker, JTM .
DISEASES OF THE COLON & RECTUM, 2001, 44 (03) :358-363
[4]   Mismatch repair proficiency and in vitro response to 5-fluorouracil [J].
Carethers, JM ;
Chauhan, DP ;
Fink, D ;
Nebel, S ;
Bresalier, RS ;
Howell, SB ;
Boland, CR .
GASTROENTEROLOGY, 1999, 117 (01) :123-131
[5]  
Chapuis PH, 1999, ANN CHIR, V53, P9
[6]   Adjuvant chemotherapy in colorectal carcinoma - Results of a meta-analysis [J].
Dube, S ;
Heyen, F ;
Jenicek, M .
DISEASES OF THE COLON & RECTUM, 1997, 40 (01) :35-41
[7]   Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer [J].
Elsaleh, H ;
Joseph, D ;
Grieu, F ;
Zeps, N ;
Spry, N ;
Iacopetta, B .
LANCET, 2000, 355 (9217) :1745-1750
[8]   p53 Gene mutation, microsatellite instability and adjuvant chemotherapy:: Impact on survival of 388 patients with Dukes' C colon carcinoma [J].
Elsaleh, H ;
Powell, B ;
Soontrapornchai, P ;
Joseph, D ;
Goria, F ;
Spry, N ;
Iacopetta, B .
ONCOLOGY, 2000, 58 (01) :52-59
[9]   CLINICOPATHOLOGICAL STAGING FOR COLORECTAL-CANCER - AN INTERNATIONAL DOCUMENTATION SYSTEM (IDS) AND AN INTERNATIONAL COMPREHENSIVE ANATOMICAL TERMINOLOGY (ICAT) [J].
FIELDING, LP ;
ARSENAULT, PA ;
CHAPUIS, PH ;
DENT, O ;
GATHRIGHT, B ;
HARDCASTLE, JD ;
HERMANEK, P ;
JASS, JR ;
NEWLAND, RC .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1991, 6 (04) :325-344
[10]   The effect of the surgeon and the pathologist on patient survival after resection of colon and rectal cancer [J].
Fleshman, JW .
ANNALS OF SURGERY, 2002, 235 (04) :464-465